Morphic
Acquired- Employees
- 51–200
- Website
- morphictx.com
- Total Funding
- $131.5M
- Last Round
- $80.0M Series BSep 2018
- Rounds
- 2
- Acquisition Date
- Jan 2024
About
Morphic develops highly differentiated molecules for autoimmune diseases, fibrotic diseases, and cancer. Its proprietary MInT Platform is used to discover therapeutically relevant small-molecule inhibitors across the integrin family. The company is developing next-generation integrin inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles, and is pursuing additional preclinical programs for pulmonary arterial hypertension and other conditions.
Summary
Morphic is a Biotech company. It has raised $131.5M in total across 2 rounds, most recently a $80.0M Series B round in Sep 2018. Investors include Omega Funds, Eli Lilly and Novo Holdings A/S.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jan 2024
Sign up to see all 4 rounds
Series A through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/morphic"><img src="https://indexed.vc/api/badge/company/morphic" alt="Morphic on Indexed.vc" width="260" height="76" /></a>